annual EBITDA:
-$86.70M+$156.41M(+64.34%)Summary
- As of today (September 16, 2025), NKTR annual EBITDA is -$86.70 million, with the most recent change of +$156.41 million (+64.34%) on December 31, 2024.
- During the last 3 years, NKTR annual EBITDA has risen by +$375.12 million (+81.23%).
- NKTR annual EBITDA is now -111.77% below its all-time high of $736.37 million, reached on December 31, 2018.
Performance
NKTR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$33.79M+$7.18M(+17.53%)Summary
- As of today (September 16, 2025), NKTR quarterly EBITDA is -$33.79 million, with the most recent change of +$7.18 million (+17.53%) on June 30, 2025.
- Over the past year, NKTR quarterly EBITDA has increased by +$10.66 million (+23.99%).
- NKTR quarterly EBITDA is now -103.42% below its all-time high of $988.28 million, reached on June 30, 2018.
Performance
NKTR quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$87.30M+$10.66M(+10.88%)Summary
- As of today (September 16, 2025), NKTR TTM EBITDA is -$87.30 million, with the most recent change of +$10.66 million (+10.88%) on June 30, 2025.
- Over the past year, NKTR TTM EBITDA has increased by +$58.73 million (+40.22%).
- NKTR TTM EBITDA is now -109.09% below its all-time high of $960.51 million, reached on June 30, 2018.
Performance
NKTR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NKTR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +64.3% | +24.0% | +40.2% |
| 3 y3 years | +81.2% | +77.2% | +81.6% |
| 5 y5 years | +77.2% | +51.3% | +76.4% |
NKTR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +81.2% | -293.2% | +77.2% | -0.7% | +81.6% |
| 5 y | 5-year | at high | +81.2% | -293.2% | +77.2% | -0.7% | +81.6% |
| alltime | all time | -111.8% | +81.2% | -103.4% | +77.2% | -109.1% | +81.6% |
NKTR EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$33.79M(-17.5%) | -$87.30M(-10.9%) |
| Mar 2025 | - | -$40.97M(-334.3%) | -$97.97M(+13.0%) |
| Dec 2024 | -$86.70M(-64.3%) | $17.49M(-158.2%) | -$86.70M(-37.1%) |
| Sep 2024 | - | -$30.04M(-32.4%) | -$137.77M(-5.7%) |
| Jun 2024 | - | -$44.45M(+49.7%) | -$146.03M(+1.1%) |
| Mar 2024 | - | -$29.70M(-11.6%) | -$144.43M(-40.6%) |
| Dec 2023 | -$243.11M(-24.7%) | -$33.59M(-12.3%) | -$243.11M(-4.9%) |
| Sep 2023 | - | -$38.29M(-10.6%) | -$255.68M(-4.2%) |
| Jun 2023 | - | -$42.85M(-66.6%) | -$266.96M(-28.3%) |
| Mar 2023 | - | -$128.37M(+178.1%) | -$372.41M(+15.3%) |
| Dec 2022 | -$323.04M(-30.1%) | -$46.16M(-6.9%) | -$323.04M(-21.4%) |
| Sep 2022 | - | -$49.57M(-66.6%) | -$410.97M(-13.4%) |
| Jun 2022 | - | -$148.30M(+87.7%) | -$474.57M(+9.1%) |
| Mar 2022 | - | -$79.01M(-41.1%) | -$434.79M(-5.9%) |
| Dec 2021 | -$461.82M(+17.6%) | -$134.09M(+18.5%) | -$461.82M(+6.6%) |
| Sep 2021 | - | -$113.17M(+4.3%) | -$433.38M(+3.9%) |
| Jun 2021 | - | -$108.53M(+2.3%) | -$417.10M(+10.4%) |
| Mar 2021 | - | -$106.04M(+0.4%) | -$377.91M(-3.8%) |
| Dec 2020 | -$392.65M(+3.2%) | -$105.65M(+9.0%) | -$392.65M(+2.6%) |
| Sep 2020 | - | -$96.89M(+39.8%) | -$382.69M(+3.5%) |
| Jun 2020 | - | -$69.33M(-42.6%) | -$369.60M(-6.7%) |
| Mar 2020 | - | -$120.78M(+26.2%) | -$396.19M(+4.1%) |
| Dec 2019 | -$380.54M(-151.7%) | -$95.69M(+14.2%) | -$380.54M(+2.8%) |
| Sep 2019 | - | -$83.80M(-12.6%) | -$370.03M(-0.1%) |
| Jun 2019 | - | -$95.93M(-8.8%) | -$370.33M(-151.9%) |
| Mar 2019 | - | -$105.13M(+23.4%) | $713.87M(-3.1%) |
| Dec 2018 | $736.37M(-1923.6%) | -$85.18M(+1.3%) | $736.37M(-8.1%) |
| Sep 2018 | - | -$84.10M(-108.5%) | $801.53M(-16.6%) |
| Jun 2018 | - | $988.28M(-1296.1%) | $960.51M(-1411.1%) |
| Mar 2018 | - | -$82.63M(+312.8%) | -$73.26M(+81.4%) |
| Dec 2017 | -$40.38M(-57.5%) | -$20.02M(-126.7%) | -$40.38M(-15.8%) |
| Sep 2017 | - | $74.88M(-264.6%) | -$47.94M(-68.4%) |
| Jun 2017 | - | -$45.50M(-8.5%) | -$151.52M(+8.3%) |
| Mar 2017 | - | -$49.75M(+80.4%) | -$139.97M(+47.2%) |
| Dec 2016 | -$95.12M(+229.0%) | -$27.57M(-3.9%) | -$95.12M(-11.0%) |
| Sep 2016 | - | -$28.70M(-15.5%) | -$106.92M(+45.2%) |
| Jun 2016 | - | -$33.95M(+593.7%) | -$73.62M(-8.0%) |
| Mar 2016 | - | -$4.89M(-87.6%) | -$80.04M(+176.8%) |
| Dec 2015 | -$28.91M(+953.8%) | -$39.37M(-957.2%) | -$28.91M(+22.7%) |
| Sep 2015 | - | $4.59M(-111.4%) | -$23.56M(-142.4%) |
| Jun 2015 | - | -$40.36M(-187.3%) | $55.51M(-27.3%) |
| Mar 2015 | - | $46.23M(-235.9%) | $76.31M(-2879.9%) |
| Dec 2014 | -$2.74M(-97.4%) | -$34.02M(-140.7%) | -$2.75M(+142.7%) |
| Sep 2014 | - | $83.66M(-527.6%) | -$1.13M(-98.7%) |
| Jun 2014 | - | -$19.57M(-40.4%) | -$87.34M(-9.5%) |
| Mar 2014 | - | -$32.83M(+1.3%) | -$96.52M(-7.8%) |
| Dec 2013 | -$104.73M(-15.1%) | -$32.40M(+1172.6%) | -$104.73M(-6.1%) |
| Sep 2013 | - | -$2.55M(-91.1%) | -$111.49M(-18.8%) |
| Jun 2013 | - | -$28.75M(-29.9%) | -$137.23M(+4.5%) |
| Mar 2013 | - | -$41.03M(+4.8%) | -$131.30M(+6.4%) |
| Dec 2012 | -$123.39M(+14.5%) | -$39.16M(+38.5%) | -$123.39M(+7.3%) |
| Sep 2012 | - | -$28.28M(+23.9%) | -$114.96M(+10.2%) |
| Jun 2012 | - | -$22.82M(-31.1%) | -$104.33M(-6.4%) |
| Mar 2012 | - | -$33.13M(+7.8%) | -$111.47M(+3.4%) |
| Dec 2011 | -$107.79M(+1055.0%) | -$30.73M(+74.0%) | -$107.79M(+16.1%) |
| Sep 2011 | - | -$17.66M(-41.1%) | -$92.84M(+21.2%) |
| Jun 2011 | - | -$29.96M(+1.7%) | -$76.62M(+91.3%) |
| Mar 2011 | - | -$29.45M(+86.6%) | -$40.05M(+329.2%) |
| Dec 2010 | -$9.33M(-87.7%) | -$15.78M(+994.0%) | -$9.33M(-262.0%) |
| Sep 2010 | - | -$1.44M(-121.8%) | $5.76M(-133.4%) |
| Jun 2010 | - | $6.61M(+417.1%) | -$17.26M(-65.1%) |
| Mar 2010 | - | $1.28M(-287.4%) | -$49.45M(-34.7%) |
| Dec 2009 | -$75.72M | -$682.00K(-97.2%) | -$75.72M(-491.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2009 | - | -$24.46M(-4.4%) | $19.36M(+22.3%) |
| Jun 2009 | - | -$25.58M(+2.4%) | $15.83M(+15.2%) |
| Mar 2009 | - | -$24.99M(-126.5%) | $13.74M(+441.2%) |
| Dec 2008 | $2.54M(-135.7%) | $94.39M(-437.2%) | $2.54M(-105.3%) |
| Sep 2008 | - | -$27.99M(+1.1%) | -$47.75M(+50.0%) |
| Jun 2008 | - | -$27.67M(-23.5%) | -$31.84M(+28.9%) |
| Mar 2008 | - | -$36.19M(-182.1%) | -$24.69M(+246.8%) |
| Dec 2007 | -$7.12M(-94.3%) | $44.10M(-465.2%) | -$7.12M(-91.4%) |
| Sep 2007 | - | -$12.08M(-41.2%) | -$82.92M(-4.2%) |
| Jun 2007 | - | -$20.53M(+10.3%) | -$86.59M(-27.6%) |
| Mar 2007 | - | -$18.62M(-41.3%) | -$119.55M(-4.9%) |
| Dec 2006 | -$125.72M(-15.4%) | -$31.70M(+101.3%) | -$125.72M(-32.7%) |
| Sep 2006 | - | -$15.75M(-70.6%) | -$186.70M(-0.7%) |
| Jun 2006 | - | -$53.49M(+115.8%) | -$188.03M(+21.4%) |
| Mar 2006 | - | -$24.78M(-73.3%) | -$154.84M(+4.2%) |
| Dec 2005 | -$148.54M(+171.3%) | -$92.67M(+442.4%) | -$148.54M(+116.0%) |
| Sep 2005 | - | -$17.09M(-15.8%) | -$68.77M(+4.1%) |
| Jun 2005 | - | -$20.30M(+9.8%) | -$66.05M(+6.2%) |
| Mar 2005 | - | -$18.48M(+43.3%) | -$62.18M(+13.1%) |
| Dec 2004 | -$54.76M(+14.6%) | -$12.90M(-10.2%) | -$54.96M(-4.1%) |
| Sep 2004 | - | -$14.37M(-12.5%) | -$57.34M(+8.8%) |
| Jun 2004 | - | -$16.43M(+45.8%) | -$52.69M(+14.4%) |
| Mar 2004 | - | -$11.27M(-26.2%) | -$46.07M(-3.6%) |
| Dec 2003 | -$47.77M(-41.1%) | -$15.28M(+57.2%) | -$47.77M(-16.5%) |
| Sep 2003 | - | -$9.72M(-0.8%) | -$57.23M(-14.5%) |
| Jun 2003 | - | -$9.80M(-24.4%) | -$66.97M(-11.0%) |
| Mar 2003 | - | -$12.97M(-47.6%) | -$75.23M(-7.2%) |
| Dec 2002 | -$81.11M(+15.4%) | -$24.74M(+27.1%) | -$81.11M(+1.2%) |
| Sep 2002 | - | -$19.46M(+7.7%) | -$80.17M(-0.1%) |
| Jun 2002 | - | -$18.06M(-4.2%) | -$80.25M(-4.3%) |
| Mar 2002 | - | -$18.85M(-20.8%) | -$83.87M(-1.6%) |
| Dec 2001 | -$70.32M(+30.9%) | -$23.79M(+21.7%) | -$85.21M(+7.5%) |
| Sep 2001 | - | -$19.55M(-9.8%) | -$79.26M(+4.8%) |
| Jun 2001 | - | -$21.68M(+7.4%) | -$75.65M(+9.2%) |
| Mar 2001 | - | -$20.19M(+13.2%) | -$69.27M(+8.5%) |
| Dec 2000 | -$53.72M(+130.2%) | -$17.84M(+11.9%) | -$63.85M(+13.8%) |
| Sep 2000 | - | -$15.94M(+4.2%) | -$56.09M(+17.3%) |
| Jun 2000 | - | -$15.30M(+3.6%) | -$47.82M(+22.2%) |
| Mar 2000 | - | -$14.77M(+46.6%) | -$39.12M(+28.1%) |
| Dec 1999 | -$23.34M(+26.9%) | -$10.08M(+31.4%) | -$30.55M(+12.1%) |
| Sep 1999 | - | -$7.67M(+16.2%) | -$27.26M(+7.4%) |
| Jun 1999 | - | -$6.60M(+6.5%) | -$25.39M(+11.5%) |
| Mar 1999 | - | -$6.20M(-8.7%) | -$22.78M(+4.2%) |
| Dec 1998 | -$18.39M(+63.0%) | -$6.79M(+17.1%) | -$21.86M(+12.9%) |
| Sep 1998 | - | -$5.80M(+45.3%) | -$19.37M(+13.7%) |
| Jun 1998 | - | -$3.99M(-24.4%) | -$17.03M(+4.9%) |
| Mar 1998 | - | -$5.28M(+22.7%) | -$16.23M(+18.5%) |
| Dec 1997 | -$11.29M(+9.6%) | -$4.30M(+24.1%) | -$13.69M(+3.8%) |
| Sep 1997 | - | -$3.46M(+8.6%) | -$13.20M(+6.1%) |
| Jun 1997 | - | -$3.19M(+16.2%) | -$12.43M(+1.5%) |
| Mar 1997 | - | -$2.74M(-27.8%) | -$12.24M(+5.6%) |
| Dec 1996 | -$10.30M(+33.8%) | -$3.80M(+40.7%) | -$11.60M(+12.6%) |
| Sep 1996 | - | -$2.70M(-10.0%) | -$10.30M(+7.3%) |
| Jun 1996 | - | -$3.00M(+42.9%) | -$9.60M(+11.6%) |
| Mar 1996 | - | -$2.10M(-16.0%) | -$8.60M(-2.3%) |
| Dec 1995 | -$7.70M(+48.1%) | -$2.50M(+25.0%) | -$8.80M(+1.1%) |
| Sep 1995 | - | -$2.00M(0.0%) | -$8.70M(+11.5%) |
| Jun 1995 | - | -$2.00M(-13.0%) | -$7.80M(+13.0%) |
| Mar 1995 | - | -$2.30M(-4.2%) | -$6.90M(+23.2%) |
| Dec 1994 | -$5.20M | -$2.40M(+118.2%) | -$5.60M(+75.0%) |
| Sep 1994 | - | -$1.10M(0.0%) | -$3.20M(+52.4%) |
| Jun 1994 | - | -$1.10M(+10.0%) | -$2.10M(+110.0%) |
| Mar 1994 | - | -$1.00M | -$1.00M |
FAQ
- What is Nektar Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Nektar Therapeutics?
- What is Nektar Therapeutics annual EBITDA year-on-year change?
- What is Nektar Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Nektar Therapeutics?
- What is Nektar Therapeutics quarterly EBITDA year-on-year change?
- What is Nektar Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Nektar Therapeutics?
- What is Nektar Therapeutics TTM EBITDA year-on-year change?
What is Nektar Therapeutics annual EBITDA?
The current annual EBITDA of NKTR is -$86.70M
What is the all time high annual EBITDA for Nektar Therapeutics?
Nektar Therapeutics all-time high annual EBITDA is $736.37M
What is Nektar Therapeutics annual EBITDA year-on-year change?
Over the past year, NKTR annual EBITDA has changed by +$156.41M (+64.34%)
What is Nektar Therapeutics quarterly EBITDA?
The current quarterly EBITDA of NKTR is -$33.79M
What is the all time high quarterly EBITDA for Nektar Therapeutics?
Nektar Therapeutics all-time high quarterly EBITDA is $988.28M
What is Nektar Therapeutics quarterly EBITDA year-on-year change?
Over the past year, NKTR quarterly EBITDA has changed by +$10.66M (+23.99%)
What is Nektar Therapeutics TTM EBITDA?
The current TTM EBITDA of NKTR is -$87.30M
What is the all time high TTM EBITDA for Nektar Therapeutics?
Nektar Therapeutics all-time high TTM EBITDA is $960.51M
What is Nektar Therapeutics TTM EBITDA year-on-year change?
Over the past year, NKTR TTM EBITDA has changed by +$58.73M (+40.22%)